Sound Bioventures backs Breye Therapeutics in €67.5 million Series A round

Breye Therapeutics raised an oversubscribed EUR 67.5 million Series A with Sound Bioventures Management AB, Mission BioCapital and Novo Holdings, targeting a randomized Phase 2 trial of danegaptide in non-proliferative diabetic retinopathy starting in 2027.